|
1
|
Korkmaz T, Seber S and Basaran G: Review
of the current role of targeted therapies as maintenance therapies
in first and second line treatment of epithelial ovarian cancer; In
the light of completed trials. Crit Rev Oncol Hematol. 98:180–188.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Woopen H, Pietzner K, Darb-Esfahani S,
Oskay-Oezcelik G and Sehouli J: Extraperitoneal response to
intraperitoneal immunotherapy with catumaxomab in a patient with
cutaneous lymphangiosis carcinomatosa from ovarian cancer: A case
report and review of the literature. Med Oncol. 29:3416–3420. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dybro A and Blaakær J: Treatment of
epithelian ovarian cancer should be followed by lymphadenectomy-a
systematic review. Ugeskr Laeger. 174:865–870. 2012.(In Danish).
PubMed/NCBI
|
|
4
|
Watts S, Prescott P, Mason J, McLeod N and
Lewith G: Depression and anxiety in ovarian cancer: A systematic
review and meta-analysis of prevalence rates. BMJ Open.
5:e0076182015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis LL and Carpenter JS: A systematic
review of nonpharmacologic interventions for treatment-related
symptoms in women with ovarian cancer. Clin J Oncol Nurs.
19:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGee J, Panabaker K, Leonard S, Ainsworth
P, Elit L and Shariff SZ: Genetics consultation rates following a
diagnosis of high-grade serous ovarian carcinoma in the Canadian
province of Ontario. Int J Gynecol Cancer. 27:437–443. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maru Y, Tanaka N, Ohira M, Itami M, Hippo
Y and Nagase H: Identification of novel mutations in Japanese
ovarian clear cell carcinoma patients using optimized targeted NGS
for clinical diagnosis. Gynecol Oncol. 144:377–383. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwon DY, Han GH, Ulak R, Ki KD, Lee JM and
Lee SK: Syndrome of inappropriate antidiuretic hormone secretion
following irinotecan-cisplatin administration as a treatment for
recurrent ovarian clear cell carcinoma. Obstet Gynecol Sci.
60:115–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sirota R, Gibson D and Kohen R: The timing
of caffeic acid treatment with cisplatin determines sensitization
or resistance of ovarian carcinoma cell lines. Redox Biol.
11:170–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gullbo J, Fryknäs M, Rickardson L, Darcy
P, Hägg M, Wickström M, Hassan S, Westman G, Brnjic S, Nygren P, et
al: Phenotype-based drug screening in primary ovarian carcinoma
cultures identifies intracellular iron depletion as a promising
strategy for cancer treatment. Biochem Pharmacol. 82:139–147. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Itamochi H, Kigawa J, Kanamori Y, Oishi T,
Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N and Ueno
NT: Adenovirus type 5 E1A gene therapy for ovarian clear cell
carcinoma: A potential treatment strategy. Mol Cancer Ther.
6:227–235. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKay TR, Bell S, Tenev T, Stoll V, Lopes
R, Lemoine NR and McNeish IA: Procaspase 3 expression in ovarian
carcinoma cells increases survivin transcription which can be
countered with a dominant-negative mutant, survivin T34A; a
combination gene therapy strategy. Oncogene. 22:3539–3547. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhan Q, Wang C and Ngai S: Ovarian cancer
stem cells: A new target for cancer therapy. Biomed Res Int.
2013:9168192013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM,
Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M,
et al: Endoglin (CD105) contributes to platinum resistance and is a
target for tumor-specific therapy in epithelial ovarian cancer.
Clin Cancer Res. 19:170–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakayama K, Nakayama N and Miyazaki K:
Development of a novel ovarian cancer molecular target therapy
against cancer-related transcriptional factor, NAC1. J Obstet
Gynaecol Res. 39:18–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gu J, Xu FK, Zhao GY, Lu CL, Lin ZW, Ding
JY and Ge D: Capn4 promotes non-small cell lung cancer progression
via upregulation of matrix metalloproteinase 2. Med Oncol.
32:512015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan
CJ, Shi YH, Huang C, Wang Z, He YF and Fan J: Capn4 overexpression
underlies tumor invasion and metastasis after liver transplantation
for hepatocellular carcinoma. Hepatology. 49:460–470. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang X, Sun J, Xia D, Can X, Liu L, Zhang
J, Xu H, Du N, Liu W, Shen F, et al: Capn4 enhances osteopontin
expression through activation of the Wnt/β-catenin pathway to
promote epithelial ovarian carcinoma metastasis. Cell Physiol
Biochem. 42:185–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song Y, Xin X, Xia Z, Zhai X and Shen K:
Selective suppression of autocatalytic caspase-3 driven by two-step
transcriptional amplified human telomerase reverse transcriptase
promoter on ovarian carcinoma growth in vitro and in mice. Oncol
Rep. 32:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brakora KA, Lee H, Yusuf R, Sullivan L,
Harris A, Colella T and Seiden MV: Utility of osteopontin as a
biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol.
93:361–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song G, Cai QF, Mao YB, Ming YL, Bao SD
and Ouyang GL: Osteopontin promotes ovarian cancer progression and
cell survival and increases HIF-1alpha expression through the
PI3-K/Akt pathway. Cancer Sci. 99:1901–1907. 2008.PubMed/NCBI
|
|
22
|
Tilli TM, Franco VF, Robbs BK, Wanderley
JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER:
Osteopontin-c splicing isoform contributes to ovarian cancer
progression. Mol Cancer Res. 9:280–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hashiguchi Y, Tsuda H, Bandera CA,
Nishimura S, Inoue T, Kawamura N, Berkowitz RS and Mok SC:
Comparison of osteopontin expression in endometrioid endometrial
cancer and ovarian endometrioid cancer. Med Oncol. 23:205–212.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao S, Wang J and Xiao N: MicroRNAs as
noninvasive biomarkers in bladder cancer detection: A diagnostic
meta-analysis based on qRT-PCR data. Int J Biol Markers.
31:e276–e285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eckert MA, Pan S, Hernandez KM, Loth RM,
Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME,
et al: Genomics of ovarian cancer progression reveals diverse
metastatic trajectories including intraepithelial metastasis to the
fallopian tube. Cancer Discov. 6:1342–1351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Zhang Z, Zhou X, Li L, Liu Q, Wang
Z, Bai X, Zhao Y, Shi H, Zhang X and Ye L: The oncoprotein HBXIP
enhances migration of breast cancer cells through increasing
filopodia formation involving MEKK2/ERK1/2/Capn4 signaling. Cancer
Lett. 355:288–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu
X, Yu Y, Zha X and Feng Y: Activation of the PI3K/AKT pathway
mediates FSH-stimulated VEGF expression in ovarian serous
cystadenocarcinoma. Cell Res. 18:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou C, Qiu L, Sun Y, Healey S, Wanebo H,
Kouttab N, Di W, Yan B and Wan Y: Inhibition of EGFR/PI3K/AKT cell
survival pathway promotes TSA's effect on cell death and migration
in human ovarian cancer cells. Int J Oncol. 29:269–278.
2006.PubMed/NCBI
|
|
30
|
Rodriguez-Brenes IA, Wodarz D and Komarova
NL: Quantifying replicative senescence as a tumor suppressor
pathway and a target for cancer therapy. Sci Rep. 5:176602015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Collet G, Szade K, Nowak W, Klimkiewicz K,
El Hafny-Rahbi B, Szczepanek K, Sugiyama D, Weglarczyk K,
Foucault-Collet A, Guichard A, et al: Endothelial precursor
cell-based therapy to target the pathologic angiogenesis and
compensate tumor hypoxia. Cancer Lett. 370:345–357. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marech I, Leporini C, Ammendola M,
Porcelli M, Gadaleta CD, Russo E, De Sarro G and Ranieri G:
Classical and non-classical proangiogenic factors as a target of
antiangiogenic therapy in tumor microenvironment. Cancer Lett.
380:216–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai Z, Zhou SL, Zhou ZJ, Bai DS, Xu XY, Fu
XT, Chen Q, Zhao YM, Zhu K, Yu L, et al: Capn4 contributes to
tumour growth and metastasis of hepatocellular carcinoma by
activation of the FAK-Src signalling pathways. J Pathol.
234:316–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin
BD, Fu HT and Zhong RQ: Diagnostic value of osteopontin in ovarian
cancer: A meta-analysis and systematic review. PLoS One.
10:e01264442015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mishra J, Drummond J, Quazi SH, Karanki
SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer
treatments and scope for combinatorial approach to enhanced cancer
cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Braunhut SJ, McIntosh D, Vorotnikova E,
Zhou T and Marx KA: Detection of apoptosis and drug resistance of
human breast cancer cells to taxane treatments using quartz crystal
microbalance biosensor technology. Assay Drug Dev Technol. 3:77–88.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tilly JL and Kolesnick RN: Sphingolipids,
apoptosis, cancer treatments and the ovary: Investigating a crime
against female fertility. Biochim Biophys Acta. 1585:135–138. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang XK, Xing H, Zheng F, Gao QL, Wang W,
Lu YP and Ma D: Role of apoptosis-associated genes and caspase-3 in
cisplatin-resistant human ovarian cancer cell lines. Zhonghua Fu
Chan Ke Za Zhi. 38:158–161. 2003.(In Chinese). PubMed/NCBI
|
